The P-III (DREAMS-2) trial assesses the safety & efficacy of mazdutide (4mg, 6mg) vs dulaglutide (1.5mg) in T2D Chinese patients (n=731) having inadequate glycemic control with metformin alone or its combinations
The study after 28wks. depicted improved HbA1c level from baseline confirming the superiority of mazdutide. Statistical superiority was seen in HbA1c change & percent change in body wt. from baseline, patient proportion with HbA1c <7.0% & ≥5% wt. loss
Mazdutide is under review for chronic weight management with the NMPA. The company anticipates P-III (DREAMS-1) study results in mid-2024 with an NDA submission for T2D to the CDE. The DREAMS-1 & DREAMS-2 data analysis will be published in academic congresses or clinical journals
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
